Fisher & Paykel Healthcare (ASX:FPH) 6-Month Price Index: 1.15 (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:FPH Fisher & Paykel Healthcare Corp Ltd ASX:FPH
90 GF Score
Price A$36.31
GF Value A$36.98
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Fisher & Paykel Healthcare 6-Month Price Index?

Fisher & Paykel Healthcare ASX:FPH +1.59% 90 6-Month Price Index is 1.15 as of Aug. 23, 2026. GuruFocus rates ASX:FPH with a GF Score™ of 90/100 and a GF Value™ of A$36.98 (Fairly Valued). The stock has 3 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-08-23), Fisher & Paykel Healthcare's 6-Month Price Index is 1.15.

Fisher & Paykel Healthcare  (ASX:FPH) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Fisher & Paykel Healthcare 6-Month Price Index Related Terms

ASX:FPH vs ISRG, BDX, MDLN: 6-Month Price Index Comparison

For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ASX:FPH
90GF Score
Fisher & Paykel Healthcare Corp Ltd ASX:FPH
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fisher & Paykel Healthcare  (ASX:FPH) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 1.15 mean?
Fisher & Paykel Healthcare (ASX:FPH) has a 6-Month Price Index of 1.15 as of Aug. 23, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Fisher & Paykel Healthcare and its competitors.
Is Fisher & Paykel Healthcare's 6-Month Price Index too high?
Fisher & Paykel Healthcare's current 6-Month Price Index is 1.15. Overall, Fisher & Paykel Healthcare has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's 6-Month Price Index compare to ISRG and BDX?
Fisher & Paykel Healthcare's 6-Month Price Index of 1.15 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Medical Devices & Instruments company?
A good 6-Month Price Index depends on the Medical Devices & Instruments industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Fisher & Paykel Healthcare and its competitors. Fisher & Paykel Healthcare's current 6-Month Price Index is 1.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Fairly Valued. The stock's GF Value™ is A$36.98, compared to a current price of A$36.31 — trading 1.8% below its estimated fair value. The current 6-Month Price Index is 1.15. Fisher & Paykel Healthcare's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current 6-Month Price Index is 1.15 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?

Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued. The current stock price of A$36.31 is trading 1.8% below its estimated GF Value™ of A$36.98. GuruFocus considers Fisher & Paykel Healthcare to be Fairly Valued.

Key valuation signals for ASX:FPH:

  • 6-Month Price Index: 1.15
  • GF Value™: A$36.98 vs. price of A$36.31 (1.8% below fair value)
  • GF Score™: 90/100 with 3 warning signs

No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fisher & Paykel Healthcare Business Description

Other Exchanges FSPKF:USAFPH:New Zealand
Address 15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
90GF Score

Get the complete analysis for ASX:FPH

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$36.31
Price
A$36.98
GF Value